OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time

Net adverse clinical events (NACE)

Monotherapy with a P2Y12 inhibitor after a minimum period of DAPT following percutaneous
 coronary intervention (PCI) is an emerging de-escalation antiplatelet strategy in recent
 years. However, the optimal timing for de-escalating DAPT in ACS patients undergoing PCI
 remains debated. The OPT-CAD score is a risk stratification tool derived from Chinese
 patients which has been demonstrated superior predictive capabilities for ischemic events and
 all-cause mortality than the GRACE score. Therefore, we hypothesize that the OPT-CAD score
 can be used to guide the timing of the DAPT de-escalation strategy to monotherapy with P2Y12
 inhibitors for ACS patients, that is, low-risk patients could be de-escalated after 1 month,
 while high-risk patients could be de-escalated after 3 months, so as to achieve
 individualized antithrombotic therapy and maximize patient benefit.